PATENT

PE S/N 09/150813

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

David J. Grainger et al.

Examiner:

Joseph Murphy

Serial No.:

09/150813

Group Art Unit:

1646 1543.002US1

Filed:

September 11, 1998 Docket:

1343.00

Title: COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicants have included the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 19-0743.

Serial No :09/150813

Filing Date: September 11, 1998

Title: COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

DAVID J. GRAINGER ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date MUCh 181 2019

Janet E. Embrets

Reg. No. 39,665

Name

Signature

PTO/SB/08A(10-01)
Approved for use through 10/31/2002 OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO INFORMATION DISCLOSURE 09/150813 **Application Number** STATEMENT BY APPLICANT September 11, 1998 Filing Date Grainger, David **First Named Inventor Group Art Unit** 1646 Murphy, Joseph **Examiner Name** Attorney Docket No: 1543.002US1 Sheet 1 of

	US PATENT DOCUMENTS											
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate						

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²			

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		FOX, DANIEL J., "Design, Synthesis, and Preliminary Pharmacological Evaluation of N-Acyl-3-aminoglutarimides as Broad-Spectrum Chemokine Inhibitors in Vitro and Anti-inflammatory Agents in Vivo", <u>J. Med. Chem., 45,</u> (2002),pp. 360-370	